Correlation between p16 expression and malignant risk of gastrointestinal stromal tumor: Evidence from nine studies

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1458-1463

  Zong, Liang ^a   Chen, Ping ^a   Jiang, Jian ^a   Wang, Hao ^a   Wang, Lei ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

Gastrointestinal stromal tumors; Malignant risk; Meta analysis; NlH; p16 protein

Indexed keywords

PROTEIN P16;

ACCURACY; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; MALIGNANT TRANSFORMATION; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION; GENES, P16; HUMANS; RISK FACTORS;

EID: 84865200508     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11473     Document Type: Article

References (35)

1. George S, Desai J: Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Curr Treat Options Oncol 2002; 3:489-496.
2. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
3. Heinrich MC, Corless CL, Duensing A, et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710.
4. Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterol 2003; 125:660-667.
5. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459-465.
6. Kawaguchi K, Oda Y, Saito T, et al.: Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J Pathol 2003; 201:487-495.
7. Gessner C, Liebers U, Kuhn H, et al.: BAX and p16INK4A are independent positive prognostic markers for advanced tumor stage of non-small cell lung cancer. Eur Respir J 2002; 19:134-140.
8. Hilton DA, Penney M, Evans B, Sanders H, Love S: Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 2002; 26:472-478.
9. Mäkitie AA, MacMillan C, Ho J, et al.: Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003; 9:2177-2184.
10. Nakamura N, Yamamoto H, Yao T, et al.: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 2005; 36(7):828-837.
11. Sabah M, Cummins R, Leader M, Kay E: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 2006; 37(6):648-655.
12. Yang WL, Yu JR, Wu YJ, et al.: Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics and surgical prognosis. J Surg Oncol 2009; 100(7):606-610.
13. Tetikkurt US, Ozaydin IY, Ceyian S, et al.: predicting malignant potential of gastrointestinal stromal tumors: role of p16 and e2f1 expression. Appl Immunohistochem Mol Morphol 2010; 18(4):338-343.
14. Riccardo Ricci: Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004; 122:35-43.
15. Schneider-Stock R, Boltze C: High prognostic value of p16ink4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003; 21(9):1688-1697.
16. Schneider-Stock R: Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clinical Cancer Res 2005; 11:638-645.
17. Zhang Y, Cao H, Wang M, et al.: Loss of chromosome 9p21 and decreased p16 expression correlate with malignant gastrointestinal stromal tumor. World J Gastroenterol 2010; 16(37):4716-4724.
18. Huang HY, Huang WW, Lin CN, et al.: Immunohistochemical expression of p16ink4a, ki-67, and mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria. Ann Surg Oncol 2006; 13(12):1633-1644.
19. Haller F, Gunawan B, Von Heydebreck A, et al.: Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 2005; 11(18):6589-9657.
20. Nemoto Y, Mikami T, Hana K, et al.: Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1 Pathol Internat 2006; 56:724-731.
21. Steigen SE, Bjerkehagen B, Haugland HK, et al.: Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Modern Pathol 2008; 21:46-53.
22. Schmieder M, Wolf S, Danner B, et al.: p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia 2008; 10:1154-1162.
23. Haller F, Löbke C, Ruschhaupt M, et al.: Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 2008; 215:253-262.
24. Kang YN, Jung HR, Hwang I: Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat 2010; 42(3):135-143.
25. House MG, Guo M, Efron DT, et al.: Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 2003; 7:1004-1014.
26. Romeo S, Debiec-Rychter M, Van Glabbeke M, et al.: European organization for research and treatment of cancer soft tissue and bone sarcoma group. Clin Cancer Res 2009; 15:4191-4198.
27. Park CK: Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 2008; 247:1011-1018.
28. Sabah M, Cummins R, Leader M, Kay E: Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Modern Pathol 2004; 17:1364-1371.
29. Liang JF, Zheng HX, Li N, et al.: Prognostic value of p16 gene methylation and p16 protein expression in gastrointestinal stromal tumor. Chin J Gastrointest Surg 2007; 10:372-375.
30. Serrano M, Lee H, Chin L, et al.: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27-37.
31. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-756.
32. Reed AL, Califano J, Cairns P, et al.: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56:3630-633.
33. Caldas C, Hahn SA, da Costa LT, et al.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27-32.
34. Schutte M, Hruban RH, Geradts J, et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57:3126-3130.
35. El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al.: DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000; 60:3899-3903.